FCP
BSX icon

Fidelis Capital Partners’s Boston Scientific BSX Stock Holding History

Fidelis Capital Partners’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Sell
14,089
-3,184
-18% -$173K 0.03% 305
2026
Q1 		$1.08M Buy
17,273
+177
+1% +$14.2K 0.08% 201
2025
Q4 		$1.63M Buy
17,096
+404
+2% +$39.6K 0.12% 141
2025
Q3 		$1.63M Sell
16,692
-76
-0.5% -$7.87K 0.13% 139
2025
Q2 		$1.73M Buy
16,768
+239
+1% +$24.2K 0.16% 113
2025
Q1 		$1.68M Sell
16,529
-1
-0% -$101 0.18% 102
2024
Q4 		$1.7M Buy
16,530
+2,621
+19% +$231K 0.17% 106
2024
Q3 		$1.22M Sell
13,909
-1,199
-8% -$94.5K 0.14% 126
2024
Q2 		$1.11M Buy
15,108
+1,263
+9% +$92.4K 0.16% 115
2024
Q1 		$948K Buy
13,845
+809
+6% +$52K 0.14% 136
2023
Q4 		$754K Buy
13,036
+4,138
+47% +$221K 0.17% 124
2023
Q3 		$470K Buy
8,898
+788
+10% +$41.3K 0.16% 137
2023
Q2 		$439K Sell
8,110
-292
-3% -$15.3K 0.16% 143
2023
Q1 		$433K Buy
+8,402
New +$396K 0.18% 132

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelis Capital Partners's BSX Position: Q2 2026 in Review

Fidelis Capital Partners reduced its Boston Scientific (BSX) stake by 18% in Q2 2026, selling an estimated $173K and leaving 14,089 shares worth $601K. The position accounts for 0.03% of the portfolio, ranked #305.

Fidelis Capital Partners first reported a position in BSX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.73M in Q2 2025. 1,487 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Fidelis Capital Partners held 14,089 shares of Boston Scientific worth $601K as of Q2 2026.
  • Fidelis Capital Partners sold 3,184 Boston Scientific shares in Q2 2026, an estimated $173K.
  • Boston Scientific made up 0.03% of Fidelis Capital Partners's portfolio in Q2 2026, its #305 holding.
  • Fidelis Capital Partners first reported a position in Boston Scientific in Q1 2023 and has held it in 14 quarters since.
  • Fidelis Capital Partners's Boston Scientific position peaked at $1.73M in Q2 2025.
  • 1,487 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.